Prothena Biosciences Limited

J.m. Huber Corporation

Ab Studio Inc.

University Health Network

Novo Nordisk A/s

Ferro Corporation

Yue Liu

Robin McDaid Barbour

Philip James Dolan, Iii

Tarlochan S Nijjar

Aleksey Isarov

Peter Andrew Seubert

Jeffrey N Higaki

Svetlana Alexander

Mark E Renz

Theodore A Yednock

Avijit Chakrabartty

Kenneth Flanagan

Wenyan Cai

Jiadong Shi

Stephen Jed Tam

David Reece

Yann Charlotte Bourgeois

Mark Herndon

David Dwayne Temples

Mitchell Lee Pierce

Robin Brumby Helms

James Scott Thomas

Christopher Lamar Duck

Patrick Christopher Farrell

Nathaniel D Urban

Peter Seubert

Edward E Abbott

David Stanley Reece

Philip James Iii Dolan

Polyphosphate compositions are produced by a process that includes the steps of continuously introducing a phosphate compound into a polymerization vessel, polymerizing the phosphate compound at a temperature of 250-450° C. for a time period sufficient to form the polyphosphate composition, and continuously discharging the polyphosphate composition from the polymerization vessel. The phosphate compound can be fed to the polymerization vessel in the form of an aqueous slurry containing 5-50 wt. % of the phosphate compound. Resulting polyphosphate compositions often contain at least 8 wt. % of a polyphosphate and less than 35 wt. % of the phosphate compound.

Methods for the continuous polymerization of phosphate compounds to form polyphosphate compositions

The present application provides methods, compositions and kits for determining SHD catabody levels in a biological sample, and for treating or preventing a protein aggregation disease (PAD) in an individual. Also provided are catabodies specifically recognizing amyloid beta (Aβ) peptides and methods of use thereof.

Catabodies and methods of use thereof

The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Tau immunotherapy

This disclosure relates to bispecific antibodies or antigen-binding fragments thereof, wherein the bispecific antibodies or antigen-binding fragments thereof specifically bind to two different antigens with different binding affinities.

Bispecific antibodies and uses thereof

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Antibodies recognizing tau

The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

Anti-transthyretin antibodies

Compositions containing an inorganic flame retardant, an organic amphiphilic compound, an optional suspension agent, and water are disclosed. These compositions can be used to produce coatings with both flame retardancy and water repellency for a variety of substrates.

Slurry compositions for use in flame retardant and hydrophobic coatings

Processes for producing melamine octamolybdates having high thermal stability include a step of reacting molybdenum trioxide and melamine in an acidic aqueous system at a pH of less than or equal to about 4 to form a slurry of the melamine octamolybdate. The resulting melamine octamolybdate can be characterized by a decomposition onset temperature (or a temperature at a weight loss of 1%, or a temperature at a weight loss of 2%) on a thermogravimetric analysis curve of greater than 300&#xb0; C., and is useful in polymer compositions as a smoke suppressant.

High thermal stability melamine octamolybdate and use thereof as a smoke suppressant in polymer compositions

Growing community of inventors

Foster City, CA, United States of America

Yue Liu